CAMBRIDGE, Mass. – The U.S. Food and Drug Administration has given clearance to Cambridge Cognition to market its CANTAB Mobile memory assessment tool. “There is a great unmet need for effective near patient assessment tools to assess memory impairment,” said Dr Steven Powell, CEO of Cambridge Cognition, in a statement. “Access to the large U.S. healthcare market, combined with the recent investment in our U.S. operation, will help underpin the company’s revenues and its continued growth.” CANTAB Mobile is designed to detect clinically-relevant memory impairment in older adults at the point of care. It includes a computerized test of visuospatial associative learning to assess episodic memory, with optional mood and functional assessments, to help detect symptoms of depression and problems with performing regular activities of daily living. The touchscreen test, which takes under 10 minutes to complete, can be self-administered using voiceover instructions in more than 20 languages with automatic scoring accounting for age, gender and education level. All results can be accessed in a simple to interpret, one-page physician’s report using a traffic-light output for memory and mood outputs.
You are here: / / FDA clears CANTAB Mobile memory tool